A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

At a glance

  • Drugs AMG 357 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 05 May 2016 Status changed from recruiting to discontinued.
    • 06 Nov 2015 Tablets in 15 count bottles changed to 20 count bottles as reported by ClinicalTrials.gov record.
    • 04 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top